Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment-experienced people news

Show

From To
Third-line ARVs could widen treatment gap in Zimbabwe

HIV/AIDS activists in Zimbabwe have welcomed the government's move to address the problem of HIV drug resistance by introducing third-line antiretroviral drug (ARVs). But it remains unclear how the cash-strapped government will finance this, as procuring the drugs will invariably be expensive and could divert resources away from other HIV treatment efforts.

Published
12 March 2013
From
IRIN Plus News
New integrase inhibitor dolutegravir helps treatment-experienced people on failing therapy

The next-generation integrase inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for treatment-experienced people with resistance to two or more antiretroviral drug classes, researchers reported in a poster

Published
10 March 2013
By
Liz Highleyman
Can people with resistant HIV omit NRTIs when switching from a failing regimen?

Omitting nucleoside reverse transcriptase inhibitors (NRTIs) when switching from a non-suppressive regimen to a new combination with at least two active agents can reduce pill burden and

Published
07 March 2013
By
Liz Highleyman
Australian researchers project that many HIV-positive people will run out of treatment options

Running out of antiretroviral treatment options may severely curtail the life expectancy of people with HIV in resource-rich countries, according to Australian research published in

Published
22 January 2013
By
Michael Carter
Prevalence of drug-resistant HIV has fallen dramatically among antiretroviral-experienced patients in Western Europe

There has been a significant fall in the proportion of HIV-positive people in Western Europe with experience of HIV treatment who have resistance to antiretroviral

Published
22 January 2013
By
Michael Carter
Any reduction in viral load has immunologic benefits for people with HIV who have triple-class treatment failure

HIV therapy that achieves even modest reductions in viral load can have profound immunological benefits for people with triple-class treatment failure, European investigators report in the online edition

Published
08 January 2013
By
Michael Carter
Redefining Expanded Access Programs for patients with MDR-HIV

It is time to create a new paradigm to break the vicious cycle of single drug access that has failed these patients.

Published
04 December 2012
From
GMHC Treatment Issues
Raltegravir-resistant HIV stays susceptible to dolutegravir in lab

HIV resistant to the integrase inhibitor raltegravir and isolated from patients taking a failing raltegravir regimen remained largely susceptible to the integrase inhibitor dolutegravir in phenotypic susceptibility testing. Raltegravir-resistant virus carrying a mutation at position Q148 had more reduced susceptibility to dolutegravir than isolates with other raltegravir mutations.

Published
13 November 2012
From
International AIDS Society
The generic generation

In the next few years, some of the most widely used HIV drugs will come off patent in the UK. Gus Cairns asks: what are the

Published
22 October 2012
From
HIV treatment update
Mutation breaks HIV's resistance to drugs

The human immunodeficiency virus (HIV) can contain dozens of different mutations, called polymorphisms. In a recent study an international team of researchers found that one of those mutations, called 172K, made certain forms of the virus more susceptible to treatment. Soon, doctors will be able to use this knowledge to improve the drug regimen they prescribe to HIV-infected individuals.

Published
14 September 2012
From
Science Daily
← First12345...13Next →

Filter by country